BridgeMD
New treatment option for Renal Cell Cancer
Official title Using 3D Kidney Model Based on Artificial Intelligence to Assist Partial Nephrectomy: A Prospective Validation Study
ClinicalTrials.gov ID: NCT07020169
What this study is testing
- What it's testing
- The goal of this study is to develop a real-time artificial intelligence-driven 3D kidney model to assist robotic or laparoscopic partial nephrectomy: Can this AI-powered model optimize the workflow of partial nephrectomy and enhance surgical benefits?
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 80
You may be able to join if
- Ages 18-80 years, regardless of gender
- Written informed consent obtained from the patient or legally authorized representative after full protocol disclosure
- Preoperative imaging (CT/MRI) confirming clinical stage T1a or select T1b renal tumors suitable for partial nephrectomy (R.E.N.A.L. nephrometry score...
- Localized renal tumors without lymph node/distant metastasis per NCCN Guidelines® (v2023)
- Elective minimally invasive partial nephrectomy (laparoscopic/robotic) after comprehensive surgical counseling
You likely can't join if
- Multifocal renal tumors (bilateral or unilateral)
- Prior systemic anticancer therapy (targeted agents/immunotherapy/chemotherapy) within 6 months
- Absolute surgical contraindications (e.g., ASA class ≥IV, uncontrolled coagulopathy)
- Intraoperative conversion to radical nephrectomy or open approach
- Postoperative adjuvant therapy during protocol-defined follow-up (12 months)
- Major comorbidities (e.g., NYHA class III/IV heart failure, eGFR \<30 mL/min/1.73m²) affecting outcome assessment
See the full eligibility criteria
- Ages 18-80 years, regardless of gender
- Written informed consent obtained from the patient or legally authorized representative after full protocol disclosure
- Preoperative imaging (CT/MRI) confirming clinical stage T1a or select T1b renal tumors suitable for partial nephrectomy (R.E.N.A.L. nephrometry score ≤10)
- Localized renal tumors without lymph node/distant metastasis per NCCN Guidelines® (v2023)
- Elective minimally invasive partial nephrectomy (laparoscopic/robotic) after comprehensive surgical counseling
- Multifocal renal tumors (bilateral or unilateral)
- Prior systemic anticancer therapy (targeted agents/immunotherapy/chemotherapy) within 6 months
- Absolute surgical contraindications (e.g., ASA class ≥IV, uncontrolled coagulopathy)
- Intraoperative conversion to radical nephrectomy or open approach
- Postoperative adjuvant therapy during protocol-defined follow-up (12 months)
- Major comorbidities (e.g., NYHA class III/IV heart failure, eGFR \<30 mL/min/1.73m²) affecting outcome assessment
- Concurrent enrollment in treatment clinical trials
- Investigator-determined ineligibility based on risk-benefit analysis
The study team makes the final eligibility decision.
Where it's taking place
- Nanjing, Jiangsu, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 80 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Nanjing, Jiangsu, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.